Short-Acting Insulin Market - 2024-2031

January 2024 | 46 pages | ID: S34AAD631FBEEN
DataM Intelligence

Abstracts

The Short-Acting Insulin Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.

A Short-Acting Insulin Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.

By Drug

• Humalog (Lispro)*
• Apidra (Glulisine)
• Novolog/Novorapid
• Novolin (Actrapid)
• Insuman
• Humulin
• FIASP
• Admelog

By Distribution channel

• Retail Pharmacies*
• Hospital Pharmacies
• Online Pharmacies
• Others

Regional Analysis for Short-Acting Insulin Market:

• North America (U.S., Canada, Mexico)
• Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
• Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
• South America (Colombia, Brazil, Argentina, Rest of South America)
• Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

This Report Covers:

• Go-to-market Strategy.
• Neutral perspective on the market performance.
• Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
• Customized regional/country reports as per request and country level analysis.
• Potential & niche segments and regions exhibiting promising growth covered.
• Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Research Process:

Both primary and secondary data sources have been used in the global Short-Acting Insulin Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Contents

1. METHODOLOGY AND SCOPE

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. MARKET DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

3.1. Market Snippet by Drug
3.2. Market Snippet by Distribution Channel
3.3. Market Snippet by Region

4. MARKET DYNAMICS

4.1. Market Impacting Factors
  4.1.1. Drivers
    4.1.1.1. Increasing Type 1 diabetes population globally
  4.1.2. Restraints:
    4.1.2.1. Some risks of short-acting insulins
  4.1.3. Opportunity
  4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

5.1. Porter's Five Forces Analysis
5.2. PEST Analysis
5.3. Epidemiology Analysis
5.4. Supply Chain Analysis
5.5. Pricing Analysis
5.6. Regulatory Analysis
5.7. Reimbursement Analysis
5.8. Unmet Needs

6. COVID-19 ANALYSIS

6.1. Analysis of Covid-19 on the Market
  6.1.1. Before COVID-19 Market Scenario
  6.1.2. Present COVID-19 Market Scenario
  6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. BY DRUG

7.1. Introduction
  7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Segment
  7.1.2. Market Attractiveness Index, By Drug Segment
7.2. Humalog (Lispro)*
  7.2.1. Introduction
  7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
7.3. Apidra (Glulisine)
7.4. Novolog/Novorapid
7.5. Novolin (Actrapid)
7.6. Insuman
7.7. Humulin
7.8. FIASP
7.9. Admelog

8. BY DISTRIBUTION CHANNEL

8.1. Introduction
  8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution channel Segment
  8.1.2. Market Attractiveness Index, By Distribution channel Segment
8.2. Retail Pharmacies*
  8.2.1. Introduction
  8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
8.3. Hospital Pharmacies
8.4. Online Pharmacies
8.5. Others

9. BY REGION

9.1. Introduction
  9.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
  9.1.2. Market Attractiveness Index, By Region
9.2. North America
  9.2.1. Introduction
  9.2.2. Key Region-Specific Dynamics
  9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
  9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    9.2.5.1. U.S.
    9.2.5.2. Canada
    9.2.5.3. Mexico
9.3. Europe
  9.3.1. Introduction
  9.3.2. Key Region-Specific Dynamics
  9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
  9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    9.3.5.1. Germany
    9.3.5.2. U.K.
    9.3.5.3. France
    9.3.5.4. Italy
    9.3.5.5. Spain
    9.3.5.6. Rest of Europe
9.4. South America
  9.4.1. Introduction
  9.4.2. Key Region-Specific Dynamics
  9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
  9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    9.4.5.1. Brazil
    9.4.5.2. Argentina
    9.4.5.3. Rest of South America
9.5. Asia Pacific
  9.5.1. Introduction
  9.5.2. Key Region-Specific Dynamics
  9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
  9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    9.5.5.1. China
    9.5.5.2. India
    9.5.5.3. Japan
    9.5.5.4. Australia
    9.5.5.5. Rest of Asia Pacific
9.6. Middle East and Africa
  9.6.1. Introduction
  9.6.2. Key Region-Specific Dynamics
  9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
  9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

10. COMPETITIVE LANDSCAPE

10.1. Key Developments and Strategies
10.2. Company Share Analysis
10.3. Product Benchmarking
10.4. Key Companies to Watch
10.5. Company with disruptive technology
10.6. Start Up Companies

11. GLOBAL SHORT-ACTING INSULIN MARKET- COMPANY PROFILES

11.1. Eli Lilly*
  11.1.1. Company Overview
  11.1.2. Product Portfolio and Description
  11.1.3. Key Highlights
  11.1.4. Financial Overview
11.2. Sanofi Aventis
11.3. Novo Nordisk
11.4. Pfizer Inc
11.5. Biocon Ltd
11.6. Piramal Healthcare
11.7. Abbott India Ltd
11.8. Torrent Pharmaceuticals
11.9. Cadila Pharmaceuticals Ltd
11.10. Shreya Life Sciences Pvt.Ltd
11.11. Career henan chemical co
11.12. Biochempartner
11.13. BOC Sciences
11.14. Hubei xin bonus chemical co. LTD(*LIST NOT EXHAUSTIVE)

12. DATAM INTELLIGENCE

12.1. Appendix
12.2. About Us and Services
12.3. Contact Us